top of page
SPOT-MAS
MULTI-CANCER EARLY DETECTION

WHAT IS ctDNA?

​

ctDNA (circulating tumor DNA) is DNA released from cancerous cells and tumors, circulating freely in the bloodstream.

​

ctDNA analysis based on next-generation sequencing (NGS) is a global trend in early cancer detection. ctDNA can be detected through a single blood test and has been shown to be a valuable tool in early detection of cancer, especially for healthy and asymptomatic individuals.

HOW SPOT-MAS WORKS

how-spot-mas-works-1.png

Tumor cells (if any) in the body

how-spot-mas-works-2.png

Tumor cells, as they die, release small fragments of DNA into the bloodstream, which are called “circulating tumor DNA” (ctDNA).

how-spot-mas-works-3.png

A sample of blood (10ml) is drawn via a Streck tube to extract "cell-free DNA" (cfDNA) from blood plasma.

how-spot-mas-works-4.png

Next-generation sequencing is applied to detect four different features of ctDNA from tumor cells (as distinguished from cfDNA (cell-free DNA) which is released by healthy cells)

​

  • ctDNA: negative result - NO ctDNA detected

  • ctDNA+: positive result - ctDNA detected
    The SPOT-MAS test detected signs of ctDNA associated with cancer.

how-spot-mas-works-5.png

If ctDNA is detected, the origin of the signs of cancer can be predicted through machine-learning algorithms modeled on more than 20,000 cases of cancer. The result will support doctors in guiding their clients’ next steps.

HOW IS SPOT-MAS DIFFERENT FROM
HEREDITARY CANCER SCREENING TESTS?

​

Hereditary cancer screening tests look for genes with mutations linked to cancer risks, and do not tell whether you have cancer at the time of testing.

ADVANTAGES OF THE SPOT-MAS TEST

Detect five common types of cancer with just a single blood sample

aegle-spot-mas-liver.png

LIVER

aegle-spot-mas-breast.png

BREAST

aegle-spot-mas-lung.png

LUNG

aegle-spot-mas-colorectal.png

COLORECTAL

aegle-spot-mas-stomach.png

STOMACH

Proven accuracy

The accuracy of early cancer detection and tumor origin prediction have been validated in clinical studies.

The SPOT-MAS test is a supportive screening one, and does not replace current cancer screening guidelines.

Routine Screening Methods:
 

Breast Cancer - X-ray and Mammogram
Liver Cancer - X-ray, CT-SCAN, MRI
Lung Cancer - Low-dose CT (imaging)
Colorectal Cancer - Colonoscopy
Stomach Cancer - Gastroscopy

WHO SHOULD TAKE THE SPOT-MAS TEST?

RECOMMENDED FOR

SPOT-MAS-recommended-for-1.png

People aged 40 or older​

SPOT-MAS-recommended-for-2.png

Adults with an elevated risk of cancer(*) or family history of cancer

NOT RECOMMENDED FOR

SPOT-MAS-not-recommended-for-1.png

Pregnant women

SPOT-MAS-not-recommended-for-1.png

People with symptoms of cancer or who have been diagnosed with cancer

SPOT-MAS-not-recommended-for-3.png

People with tumors/lesions that could interfere with ctDNA signals

SPOT-MAS-not-recommended-for-4.png

People who have had a marrow transplant or whole blood transfusion within 3 months of the test.

*Smoking more than 20 packs per year or passive smokers; who drink more than 4,875 ml (15 cans) per week for men and 2,600 ml (8 cans) per week for women; people who are constantly exposed to toxic substances or a polluted environment.

UNDERSTANDING SPOT-MAS RESULTS

​

The results of the SPOT-MAS test will be sent to clients within 30 days of the date your sample arrived at the Gene Solutions laboratory. The two possible test results are: “ctDNA detected” or “No ctDNA detected”:

ctDNA detected

People Aged 40 or older

  • Signs of ctDNA associated with tumor cancer have been detected in the blood sample.

  • The result will include 1-2 predictions of the origins of the tumor in the body that the cancer signal may be coming from.
     

Next step:
​

  • The ctDNA detected in the SPOT-MAS test result is not a cancer diagnosis and requires follow-up recommended diagnostic test guidelines, such as imaging prescribed by your doctor to officially confirm a cancer diagnosis.

No ctDNA detected

  • The SPOT-MAS test looked for signs of cancer and did not find any at this moment.
     

Next step:
​

  • Continue with the SPOT-MAS test or any cancer screening method every six months to one year as recommended by a healthcare professional.

  • Do not ignore cancer signs or symptoms if they occur, as this can lead to a delayed diagnosis.

     

For bookings and inquiries:

+63.2.8737.0077 | +63.917.821.9795 | +63.949.889.6237
info@aeglewellnesscenter.com

SCREEN FOR THE FIVE COMMON TYPES OF CANCER
WITH JUST A SINGLE BLOOD SAMPLE

LIVER | BREAST | LUNG | COLORECTAL | STOMACH

​

SPOT-MAS (Screening for the Presence of Tumor by Methylation And Size), a multi-cancer early detection test that applies next-generation sequencing (NGS) to detect circulating tumor DNA (ctDNA) is now available at
Aegle Wellness Center

IMPORTANT SAFETY INFORMATION

The SPOT-MAS test is recommended for use in adults with elevated risk of cancer, such as those aged 40 years or older, those who carry genetic mutations, or those with unhealthy habits like smoking, drinking alcohol, getting hepatitis B, C. SPOT-MAS is not recommended for pregnant women or patients undergoing cancer treatment, or those with a history of bone marrow transplant or blood transfusion in the past 3 months.

The SPOT-MAS test is used to detect signals that suggest cancer through ctDNA released from cancer cells into the bloodstream and to predict the tumor origin of the cancer signal in the body. SPOT-MAS does not detect all cancers and not all cancers can be detected through ctDNA analysis. Therefore, SPOT-MAS should be used as recommended by your doctor and as a supporting method for recommended routine cancer screening methods to help detect cancer EARLY.​

It should be noted that SPOT-MAS is a screening test and SPOT-MAS results should be interpreted by a healthcare expert or a genetic specialist. Your doctor will discuss the results of the SPOT-MAS test with you based on information from your medical history, clinical symptoms, and other signals. A negative SPOT-MAS test result “no ctDNA signal detected” does not exclude all possibilities of having cancer, so it is still necessary for a routine cancer check-up as recommended by a healthcare professional. With a positive SPOT-MAS test result “ctDNA signal detected” and the origin of cancer prediction, your doctor will recommend follow-up diagnostic methods such as imaging, biopsy, etc. to confirm the presence of cancer. False positives and false negatives do occur.​

When using SPOT-MAS tests for early cancer screening, some limitations of the ctDNA analysis method released from cancer cells into peripheral blood should be kept in mind:​
 

  • A negative result (no ctDNA detected) does not completely exclude the presence of cancer because the tumor might be out of the screening range (5 types) or located where it is difficult for ctDNA to release, or the secondary cancer has completely different methylation changes than the primary cancer.​

  • The sensitivity is 73.9%, meaning that for every 100 cases of cancer, about 26 cases will be missed. It is recommended that this test be used as an adjunct to screening, not a substitute for current recommended routine cancer screening methods.​

  • A positive result (ctDNA detected) does not completely confirm that the participant has cancer due to some special physiological or pathological circumstances that can produce a “false positive” result. The specificity is 95.9%, which means that for every 100 cancer-free cases, about 4 will have positive ctDNA signals

  • The positive predictive value of the test is 60%, which means that for every 100 cases that are positive, 60 will have cancer. Therefore, a positive result should be interpreted by and discussed with an oncologist or genetic specialist and confirmed with medical imaging tests.​

  • The tumor origin is predicted based on machine learning algorithms that analyze 4 different features of ctDNA released to the bloodstream and predict the tumor origins with an accuracy of 83.3%. However, these features of ctDNA can be duplicated, leading to the inability to completely identify the tumor origin.​

bottom of page